EP2563121A4 - Methods and compositions for protecting against neurotoxic agents - Google Patents
Methods and compositions for protecting against neurotoxic agentsInfo
- Publication number
- EP2563121A4 EP2563121A4 EP11775615.5A EP11775615A EP2563121A4 EP 2563121 A4 EP2563121 A4 EP 2563121A4 EP 11775615 A EP11775615 A EP 11775615A EP 2563121 A4 EP2563121 A4 EP 2563121A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- protecting against
- neurotoxic agents
- against neurotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/771,476 US20100310609A1 (en) | 2007-10-25 | 2010-04-30 | Compositions and methods for treatment of neurodegenerative diseases |
US41389910P | 2010-11-15 | 2010-11-15 | |
US201161454409P | 2011-03-18 | 2011-03-18 | |
PCT/US2011/034508 WO2011137317A1 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for protecting against neurotoxic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2563121A1 EP2563121A1 (en) | 2013-03-06 |
EP2563121A4 true EP2563121A4 (en) | 2016-05-11 |
Family
ID=44861925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11775615.5A Withdrawn EP2563121A4 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for protecting against neurotoxic agents |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2563121A4 (en) |
JP (1) | JP5941908B2 (en) |
KR (1) | KR20130113314A (en) |
CN (1) | CN103002734A (en) |
AU (1) | AU2011245223B2 (en) |
BR (1) | BR112012027905A2 (en) |
CA (1) | CA2798127A1 (en) |
EA (1) | EA201201483A1 (en) |
IL (1) | IL222757A0 (en) |
MX (1) | MX2012012634A (en) |
WO (1) | WO2011137317A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
BR112013003110A2 (en) * | 2010-08-12 | 2016-06-28 | Revalesio Corp | compositions and methods for the treatment of taupathy |
JP6159584B2 (en) * | 2012-06-14 | 2017-07-05 | 松本 高明 | Infusion, infusion production method and infusion device |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
US20180243247A1 (en) * | 2017-02-28 | 2018-08-30 | Bryan J. Katz | Drug combinations for cerebrovascular disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05010042A (en) * | 2003-03-20 | 2006-05-25 | Aquaphotonics Inc | Micro-cluster compositions. |
ITMI20061737A1 (en) * | 2006-09-12 | 2008-03-13 | Snam Progetti | PROCEDURE FOR THE TRANSPORT OF SULFUR TO LOW RISK AND TO ZERO EMISSION FROM SOLID SULFUR DEPOSITS IN BLOCKS OF CONSIDERABLE DIMENSIONS |
US20100310609A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Compositions and methods for treatment of neurodegenerative diseases |
US9745567B2 (en) * | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
WO2009134728A2 (en) * | 2008-04-28 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
-
2011
- 2011-04-29 MX MX2012012634A patent/MX2012012634A/en not_active Application Discontinuation
- 2011-04-29 CA CA2798127A patent/CA2798127A1/en not_active Abandoned
- 2011-04-29 BR BR112012027905A patent/BR112012027905A2/en not_active IP Right Cessation
- 2011-04-29 JP JP2013508277A patent/JP5941908B2/en not_active Expired - Fee Related
- 2011-04-29 WO PCT/US2011/034508 patent/WO2011137317A1/en active Application Filing
- 2011-04-29 KR KR1020127031216A patent/KR20130113314A/en not_active Application Discontinuation
- 2011-04-29 EP EP11775615.5A patent/EP2563121A4/en not_active Withdrawn
- 2011-04-29 CN CN2011800318038A patent/CN103002734A/en active Pending
- 2011-04-29 AU AU2011245223A patent/AU2011245223B2/en not_active Ceased
- 2011-04-29 EA EA201201483A patent/EA201201483A1/en unknown
-
2012
- 2012-10-29 IL IL222757A patent/IL222757A0/en unknown
Non-Patent Citations (5)
Title |
---|
ASHUTOSH AGARWAL ET AL: "Principle and applications of microbubble and nanobubble technology for water treatment", CHEMOSPHERE., vol. 84, no. 9, 1 August 2011 (2011-08-01), GB, pages 1175 - 1180, XP055234995, ISSN: 0045-6535, DOI: 10.1016/j.chemosphere.2011.05.054 * |
CHAPLIN MARTIN: "Nanobubbles (ultrafine bubbles)", 6 November 2015 (2015-11-06), pages 1 - 12, XP055235029, Retrieved from the Internet <URL:http://www1.lsbu.ac.uk/water/nanobubble.html> [retrieved on 20151209] * |
LEE ET AL: "Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity", TOXICOLOGY, LIMERICK, IR, vol. 243, no. 1-2, 14 December 2007 (2007-12-14), pages 43 - 50, XP022391166, ISSN: 0300-483X * |
See also references of WO2011137317A1 * |
USHIKUBO F Y ET AL: "Evidence of the existence and the stability of nano-bubbles in water", COLLOIDS AND SURFACES. A, PHYSICACHEMICAL AND ENGINEERING ASPECTS, ELSEVIER, AMSTERDAM, NL, vol. 361, no. 1-3, 20 May 2010 (2010-05-20), pages 31 - 37, XP027030201, ISSN: 0927-7757, [retrieved on 20100311] * |
Also Published As
Publication number | Publication date |
---|---|
JP5941908B2 (en) | 2016-06-29 |
IL222757A0 (en) | 2012-12-31 |
KR20130113314A (en) | 2013-10-15 |
CN103002734A (en) | 2013-03-27 |
CA2798127A1 (en) | 2011-11-03 |
EA201201483A1 (en) | 2013-04-30 |
BR112012027905A2 (en) | 2015-09-08 |
EP2563121A1 (en) | 2013-03-06 |
MX2012012634A (en) | 2013-02-26 |
AU2011245223B2 (en) | 2015-11-19 |
AU2011245223A1 (en) | 2013-01-10 |
JP2013529195A (en) | 2013-07-18 |
WO2011137317A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263729A (en) | Compositions and methods for the removal of biofilms | |
HK1246715A1 (en) | Compositions and methods for targeted thermomodulation | |
GB201014618D0 (en) | Respirtory protection equipment | |
ZA201209259B (en) | Uses and compositions | |
EP2552953A4 (en) | Frizzled-binding agents and uses thereof | |
ZA201208948B (en) | Modified beta-lactamases and methods and uses related thereto | |
EP2629742A4 (en) | Hair-mending compositions and associated methods | |
EP2575825A4 (en) | Compositions and methods for treating depression | |
GB201113485D0 (en) | Corrosion protection | |
PL2501847T3 (en) | Protective glove | |
EP2533645A4 (en) | Methods and compositions for improving cognitive function | |
EP2563121A4 (en) | Methods and compositions for protecting against neurotoxic agents | |
EP2601269A4 (en) | Anti-settling compositions and methods for use | |
EP2609160A4 (en) | Protective coating composition | |
EP2632460A4 (en) | Compositions and methods for treating tuberculosis | |
HK1167522A1 (en) | Protection device | |
HK1201451A1 (en) | Compositions and methods | |
GB201018650D0 (en) | Methods and compositions | |
EP2931280A4 (en) | Methods and compositions for inhibiting cnksr1 | |
HK1254904B (en) | Compositions and methods for the alteration of xlhed phenotypes | |
HK1170854A1 (en) | Combination of appliances for protecting against surges | |
HK1167521A1 (en) | Protection device | |
EP2686335A4 (en) | Decorin compositions and use thereof | |
HK1167350A1 (en) | Methods and compositions for protecting and treating neuroinjury | |
EP2603610A4 (en) | Methods and compositions for diagnosing and treating lupus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121129 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160407 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20170317 |